Literature DB >> 32127463

Implementation of targeted screening for lung cancer in a high-risk population within routine NHS practice using low-dose computed tomography.

Helen Grover1,2, Thomas Ross3, Elizabeth Fuller2,4.   

Abstract

We report a primary care-based lung cancer targeted screening programme using low-dose CT (LDCT) in South Tyneside and Sunderland. Ever smokers with ≥10 pack-years aged 55-74 years were identified at annual COPD review. 925 individuals attended for LDCT. 2% (n=19/925) had lung cancer diagnosed. 66.7% (n=14/21) had early stage disease and 78.9% (n=15/19) were offered treatment with curative intent. 79.3% of individuals attending for LDCT were ranked in the lowest deprivation quintiles. This approach has been successfully established in routine NHS practice; it is effective with improvements in stage of disease and engages individuals in deprived areas. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  lung cancer

Year:  2020        PMID: 32127463     DOI: 10.1136/thoraxjnl-2019-214303

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  3 in total

1.  Overdiagnosis in lung cancer screening.

Authors:  Matthew E J Callister; Peter Sasieni; Hilary A Robbins
Journal:  Lancet Respir Med       Date:  2021-01       Impact factor: 30.700

2.  Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom.

Authors:  Hilary A Robbins; Karine Alcala; Anthony J Swerdlow; Minouk J Schoemaker; Nick Wareham; Ruth C Travis; Philip A J Crosbie; Matthew Callister; David R Baldwin; Rebecca Landy; Mattias Johansson
Journal:  Br J Cancer       Date:  2021-04-12       Impact factor: 9.075

3.  Socio-economic inequalities in cancer survival: how do they translate into Number of Life-Years Lost?

Authors:  Aimilia Exarchakou; Dimitra-Kleio Kipourou; Aurélien Belot; Bernard Rachet
Journal:  Br J Cancer       Date:  2022-02-11       Impact factor: 9.075

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.